KALAMAZOO, Mich.-- Medical device maker Stryker Corp. on Monday named Kevin Lobo, the president of its orthopedics business, as its new president and CEO, effective immediately.
*Lobo succeeds interim CEO Curt Hartman. Oct 1- Medical device maker Stryker Corp on Monday named Kevin Lobo, a unit president hired just last year, as chief executive, succeeding Curt Hartman, who had held the position on an interim basis.
Oct 1- Medical device maker Stryker Corp named Kevin Lobo as Chief Executive. Interim CEO Curt Hartman resigned and will stay on as an adviser to assure a smooth transition, the company said. Lobo, who joined Stryker in April 2011, was the president for its orthopedics unit.
*Stryker names kevin a. lobo as president and chief executive officer.
Oct 1- Medical device maker Stryker Corp on Monday named Kevin Lobo, head of its orthopedics unit, as president and chief executive following an eight-month search.
The sluggish economy is prompting more Americans to put off medical tests, prescriptions and so-called elective procedures—like knee or hip replacements—and related health care companies are feeling the pain.
Take a look at some of Thursday’s morning movers.
Check out which companies are making headlines after the bell Wednesday:
Take a look at some of Thursday's midday movers:
Take a look at some of Friday's midday movers:
Check out which companies are making headlines after-the-bell Tuesday:
After the housing bubble and the Internet bubble before that, you'd think we'd learn our lesson. But apparently not.
The bulls are back in Stryker.
Take a look at some of Thursday morning's early movers:
Chief executives at some of the biggest U.S. biotech and pharmaceutical companies are at the annual JPMorgan health care conference in San Francisco. Here's what some of them told CNBC on Tuesday.
Option bulls are looking for Stryker to leg higher.
To get an idea of which S&P 500 index companies have high levels of insider ownership, CNBC’s analyst Giovanny Moreano compiled the numbers with data from Capital IQ and Thomson Reuters.
Stephen MacMillan, Stryker Chairman & CEO, discusses whether the company is under pressure as the stock underperforms even more than the broader market.
With shares down about 20% over the past 3 months, how should you trade Stryker?
Options Action trader, Mike Khouw with an outlook on Stryker and whether it is set to surge.